Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea-Reference-Cited by-同舟云学术

Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea

Published:2020-12-31 Issue:4 Volume:55 Page:246-252
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Choi Eun Jin¹,Hwang Tai ju²,Choi Yong Mook³,Kim Hugh Chul⁴,Yoo Myung Chul⁵,Song Haylee⁶,Badejo Kayode⁷

Affiliation:

1. Department of Pediatrics, Daegu Catholic University Medical Center, Daegu, Korea

2. Korea Hemophilia Foundation Clinic, Gwangju, Korea

3. Korea Hemophilia Foundation Clinic, Seoul, Korea

4. HughChul Kim Internal Medicine Clinic, Seoul, Korea

5. Sunchun Chung Hospital, Seoul, Korea

6. Hematology, Growth and Emerging Markets, Takeda Pharmaceutical International, Singapore

7. Global Patient safety Evaluation, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://pdf.medrang.co.kr/BR/2020/055/BR-55-246.pdf

Reference27 articles.

1. Konkle BA, Huston H, Nakaya Fletcher S. GeneReviews. Seattle, WA: University of Washington, 2000 (Accessed September 5, 2019, https://www.ncbi.nlm.nih.gov/books/NBK1495/pdf/Bookshelf_NBK1495.pdf).

2. Haemophilias A and B

3. World Federation of Hemophilia. Report on the Annual Global Survey 2018. Montreal, Canada: World Federation of Hemophilia, 2019 (Accessed January 28, 2019, http://www1.wfh.org/publications/files/pdf-1731.pdf).

4. World Federation of Hemophilia. Report on the Annual Global Survey 2012. Montreal, Canada: World Federation of Hemophilia, 2013 (Accessed November 15, 2019, https://www1.wfh.org/publications/files/pdf-1574.pdf).

5. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects